Key facts
- This page summarizes Rafael Amado's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Oct 2022, 16:35.
Rafael Amado - 07 Oct 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)
- Reporting relationship
- EVP of R&D
- Issuer ticker
- ALLO
- Reported as of
- 07 Oct 2022
- Net transaction value
- -$100,099
- SEC form
- 4
- Accepted by SEC
- 11 Oct 2022, 16:35:42 UTC
- Prior SEC filing
- 05 Oct 2022
- Next SEC filing
- 03 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Veer Bhavnagri, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rafael Amado filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 11 Oct 2022.
Change
- Previous filing in this sequence was filed on 05 Oct 2022.
- Current net transaction value: -$100,099.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALLO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +19,120
- Change %
- +3.6%
- Price
- $0.000000
- Shares after
- 550,410
- Date
- 07 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
ALLO
transaction
Common Stock
Tax liability
- Transaction value
- $100,099
- Shares
- -8,464
- Change %
- -1.5%
- Price
- $11.83
- Shares after
- 541,946
- Date
- 07 Oct 2022
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on September 3, 2019. Performance RSUs vested upon the initiation of a Phase 2 clinical trial of ALLO-501A. Each Performance RSU represents the right to receive one share of common stock of the Issuer.
Footnote F2
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7081 to $11.845, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.